Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 1,860,000 shares, a growth of 69.1% from the May 15th total of 1,100,000 shares. Based on an average trading volume of 310,900 shares, the short-interest ratio is presently 6.0 days.

Institutional Trading of Aligos Therapeutics

Several hedge funds have recently added to or reduced their stakes in ALGS. Acadian Asset Management LLC lifted its stake in Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after purchasing an additional 98,628 shares during the last quarter. Newtyn Management LLC raised its stake in shares of Aligos Therapeutics by 2.2% during the third quarter. Newtyn Management LLC now owns 920,000 shares of the company’s stock valued at $687,000 after acquiring an additional 20,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Aligos Therapeutics by 1.6% during the third quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company’s stock valued at $755,000 after acquiring an additional 15,905 shares during the last quarter. Opaleye Management Inc. bought a new position in shares of Aligos Therapeutics during the fourth quarter valued at about $861,000. Finally, Altitude Crest Partners Inc. bought a new position in shares of Aligos Therapeutics during the fourth quarter valued at about $1,889,000. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Stock Performance

Shares of NASDAQ:ALGS opened at $0.50 on Friday. Aligos Therapeutics has a 52-week low of $0.49 and a 52-week high of $1.20. The firm has a fifty day moving average of $0.72 and a 200 day moving average of $0.75. The firm has a market capitalization of $39.06 million, a PE ratio of -0.39 and a beta of 2.28.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $0.99 million during the quarter. Aligos Therapeutics had a negative return on equity of 144.16% and a negative net margin of 783.72%. On average, sell-side analysts forecast that Aligos Therapeutics will post -0.73 EPS for the current fiscal year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).